Lea Krekow

Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling

Frankie A. Holmes, Virginia Espina, Lance A. Liotta et al. · BMC Research Notes · 2013 · 74 citations · Full text

Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine

Joyce O’Shaughnessy, Hartmut Koeppen, Yuanyuan Xiao et al. · Clinical Cancer Research · 2015 · 58 citations

Quantitative measurement of HER2 expression in breast cancers: comparison with ‘real-world’ routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival

Denise A. Yardley, Peter A. Kaufman, Weidong Huang et al. · Breast Cancer Research · 2015 · 45 citations · Full text

Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer

Joyce O’Shaughnessy, D Paul, Christopher Stokoe et al. · Cancer Research · 2010 · 39 citations

Breast Oncology, Primary Endpoint, Immunology +19

Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study

Denise A. Yardley, James A. Reeves, Elizabeth Claire Dees et al. · Clinical Breast Cancer · 2016 · 32 citations